Biotechnology Sector Funding Environment / Investor Risk Appetite: Global economic concerns, potentially exacerbated by the Middle East conflict and IMF growth forecast downgrades, can lead to a more risk-averse investor environment, impacting funding for clinical-stage biopharmaceutical companies like Alumis, which heavily rely on capital raises for research and development.

Regulatory Landscape for Drug Approvals: As Alumis is a clinical-stage company with an NDA planned for its lead product, envudeucitinib, in H2 2026, changes in regulatory pathways, approval timelines, or increased scrutiny from agencies like the FDA directly influence the company's ability to commercialize its therapies and generate revenue.

Interest Rate Environment: While a strong US economy (indicated by job growth) exists, broader inflationary pressures (partially driven by higher oil prices due to the Middle East conflict) could prompt central banks to maintain or raise interest rates. Higher interest rates increase the cost of capital for Alumis, affecting its capacity to finance extensive R&D and clinical trials, especially given its current unprofitability.